Streetbeat News

Earnings

RXRX

Recursion Pharmaceuticals (NASDAQ:RXRX) reported Q3 losses of $(0.43) per share, missing the analyst consensus estimate of $(0.39) by 10.26%. This is a 22.86% decrease from the same period last year. The company also reported quarterly sales of $10.53 million, missing the analyst consensus estimate of $12.87 million by 18.16%, a 19.96% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:00 pm

CARM

CARISMA Therapeutics has reported Q3 cash, cash equivalents, and marketable securities of $94.1M. This is expected to fund the company into the first quarter of 2025.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:58 pm

CARM

CARISMA Therapeutics (NASDAQ:CARM) reported Q3 losses of $(0.53) per share, beating the analyst consensus estimate of $(0.57) by 7.02%. This is a 93.67% increase over losses from the same period last year. The company also reported quarterly sales of $3.83 million, beating the analyst consensus estimate of $1.20 million by 218.92%. This is a 48.45% increase over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:57 pm

NVMI

Nova, a semiconductor company, expects its Q4 revenues to be between $123M and $132M, compared to the consensus estimate of $127.29M. The company also forecasts its adjusted EPS to be between $1.16 and $1.31, higher than the consensus estimate of $1.09.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:57 pm

MKTW

Marketwise reported Q3 sales of $106.15M, beating the analyst consensus estimate of $104.80M by 1.29%. However, this represents an 11.49% decrease compared to the same period last year.

Portfolio Pulse from bharat@benzinga.com

November 09, 2023 | 12:56 pm

TCRX

TScan Therapeutics (NASDAQ:TCRX) reported Q3 earnings, beating estimated earnings by 46.67% with an EPS of $-0.24 versus an estimate of $-0.45. Revenue was up $524 thousand from the same period last year. Last quarter, the company beat EPS estimates by $0.27, which was followed by a 1.9% drop in the share price the next day.

Portfolio Pulse from Benzinga Insights

November 09, 2023 | 12:55 pm

RPTX

Repare Therapeutics (NASDAQ:RPTX) reported its Q3 earnings, beating estimated earnings by 47.67% with an EPS of $-0.45 versus an estimate of $-0.86. However, revenue was down $110.39 million from the same period last year. Last quarter, the company beat on EPS by $0.5, which was followed by a 17.1% increase in the share price the next day.

Portfolio Pulse from Benzinga Insights

November 09, 2023 | 12:55 pm

NVMI

Nova (NASDAQ:NVMI) reported Q3 earnings of $1.23 per share, beating the analyst consensus estimate of $1.09 by 12.84%. However, this is a 0.81% decrease from the same period last year. The company also reported quarterly sales of $128.81 million, surpassing the analyst consensus estimate of $123.10 million by 4.64%, but this is a 10.49% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:54 pm

SONY

Sony Group Corp reported Q2 FY23 sales growth of 8% YoY to $19.58 billion, beating consensus estimates. However, adjusted EPS of $1.12 missed the consensus of $1.16. Revenue from Game & Network Services and Music segments increased by 32% and 14% respectively. The company sold 4.9 million PS5 units in the quarter, up from 3.3 million a year ago. Sony revised its FY23 sales outlook to $87.32 billion from the prior $90.37 billion. The company's shares traded lower by 1.51% at $86.22 premarket.

Portfolio Pulse from Anusuya Lahiri

November 09, 2023 | 12:53 pm

SLGL

Sol-Gel Technologies reported Q3 losses of $(0.21) per share, beating the analyst consensus estimate of $(0.23) by 8.7%. However, the company's quarterly sales of $213.00K missed the analyst consensus estimate of $690.00K by 69.13%. This represents a 40% decrease in EPS and an 18.39% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:51 pm